O
LRMR icon

OrbiMed’s Larimar Therapeutics LRMR Stock Holding History

OrbiMed’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-617,245
Closed -$9.02M – 170
2021
Q1 		$9.02M Sell
617,245
-269,315
-30% -$4.89M 0.08% 124
2020
Q4 		$19M Hold
886,560
– – 0.17% 103
2020
Q3 		$13.4M Sell
886,560
-47,400
-5% -$600K 0.17% 101
2020
Q2 		$12M Buy
933,960
+841,749
+913% +$9.8M 0.17% 92
2020
Q1 		$852K Buy
92,211
+23,794
+35% +$313K 0.01% 136
2019
Q4 		$911K Buy
+68,417
New +$654K 0.01% 133

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

OrbiMed's LRMR Position: Q2 2021 in Review

OrbiMed sold out of Larimar Therapeutics (LRMR) in Q2 2021, closing a stake of 617,245 shares — an estimated $9.02M sold.

OrbiMed first reported a position in LRMR in Q4 2019 and held it in 6 quarters. The position peaked at $19M in Q4 2020. 45 funds tracked by Wall St. Rank hold LRMR as of Q2 2021.

  • OrbiMed reported no remaining Larimar Therapeutics position as of Q2 2021 after selling out during the quarter.
  • OrbiMed sold 617,245 Larimar Therapeutics shares in Q2 2021, an estimated $9.02M.
  • OrbiMed first reported a position in Larimar Therapeutics in Q4 2019 and held it in 6 quarters.
  • OrbiMed's Larimar Therapeutics position peaked at $19M in Q4 2020.
  • 45 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2021.

Based on OrbiMed's 13F filing for Q2 2021, filed 16 Aug 2021.